Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian stock markets open firm
Fri, 19 Jul 09:30 am

The major Asian stock markets have opened on a mixed note with Japan (down 1.4%) and Taiwan (down 1.5%) leading the losses. However, the markets in Indonesia (up 0.3%) and Malaysia (up 0.4%) are trading in green. The Indian stock markets indices have opened the day on a firm note with stocks in the software and auto space leading the gains. However, the stocks in the power and banking sector are leading the losses.

The Sensex today is up by around 57 points (0.3%), while the NSE-Nifty is up by around 9 points (0.1%). Mid and small cap stocks have also opened in the green with the BSE Mid Cap and BSE Small Cap indices up by around 0.2% each. The rupee is trading at Rs 59.84 to the US dollar.

Indian Pharma stocks have opened the day on a mixed note with Indoco Remedies and J.B. Chemicals leading the gains. However, Panacea Biotech Ltd and Elder Pharma were leading the losses. As per a leading financial daily, nine drug makers are likely to be slapped with a heavy penalty of Rs 25 bn by National Pharmaceutical Pricing Authority (NPPA) over allegedly selling anti-asthma drug Doxofylline without prior price approval. The decision follows a recent Supreme Court order against the industry that brought the widely prescribed drug under price control. The penalty will be calculated in retrospect from 2009, when the price of the drug was fixed by NPPA. As per some official sources, the notice has already been sent to four drug companies - Ranbaxy, Cipla, Cadila and Glenmark - for allegedly overcharging on sale of their individual brands containing Doxofylline. NPPA has sought details and data from others and is likely to issue notice to the rest of the firms as well.

Private Bank stocks have opened the day mainly in the red with Indusind Bank and Karnataka Bank leading the losses. Axis Bank has announced results for the first quarter ended June 2013 (1QFY14). The total income for the quarter witnessed a growth of 15.9% on a year on year (YoY) basis. The gross nonperforming assets (NPAs) of the bank at the end of the quarter stood at 1.10 % of advances as compared to 1.06 % in the corresponding quarter last year. The bank has reported a 22% YoY in the net profits for the quarter. The growth in the bottomline was boosted by higher interest income. The net interest income for the quarter grew by 31% YoY. The bank has considerable exposure to troubled infrastructure projects as well as to midsize companies facing cash-flow problems. As such, it has also increased its provisions against bad loans and contingencies in the quarter to Rs. 7.1 bn from Rs. 2.6 bn a year earlier.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets open firm". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.